Latest Research and Publications
Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study
Objective: To characterize the real-world use, efficacy, and safety of oritavancin in adult patients with acute osteomyelitis. Read more…
Efficacy of Oral Vancomycin in Preventing Recurrent Clostridium difficile Infection in Patients Treated With Systemic Antimicrobial Agents
Abstract: We compared rates of recurrent Clostridium difficile infection in patients receiving or not receiving oral vancomycin prophylaxis with systemic antimicrobial therapy. Read more…
Private Practice Infectious Disease: Metro Infectious Disease Consultants
Abstract: Despite the stimulating nature of infectious diseases (ID), fellowship programs have failed, on a yearly basis, to fill multiple positions. In addition, numerous entities have published information showing that infectious disease physicians are poorly reimbursed compared to their colleagues in other specialties and likely to feel overwhelmed. Read more…
Use of Fecal Microbiota, Live-jslm (RBL) in the Routine Clinical Management of Clostridioides Difficile—First Five Cases
Abstract: Clostridioides difficile infection (CDI) is one of the most common healthcare-associated infections. The current recommended treatment regimen for an initial episode of CDI is fidaxomicin (200 mg twice daily for 10 days) or vancomycin (125 mg, four times daily for 10 days) as an acceptable alternative. Read more…
A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline
Objective: To evaluate the efficacy and safety of eravacycline in a range of infections such as intraabdominal infections, pneumonia and diabetic foot infections in seriously ill patients. Read more…
Oritavancin Versus Daptomycin for Osteomyelitis Treatment After Surgical Debridement
Introduction: Weekly intravenous (IV) oritavancin and daily daptomycin were compared in an outpatient setting following extensive surgical debridement for treating patients with osteomyelitis. Read more…
Oral Vancomycin Prophylaxis Works!
Abstract: Background Clostridium difficile infections (CDI) cause approximately 500,000 cases a year with an estimated cost that exceeds $4.8 billion. Despite interventions that addressed environmental disinfection, antibiotic stewardship, and infection control, many institutions continue to have a significant burden of disease. Read more…
The Adherence and LDL-C Lowering Effect of Inclisiran Among Patients Who Received Treatment at Outpatient Clinics
Introduction: Inclisiran is a novel small interfering RNA (siRNA) indicated as an adjunct to diet and maximally tolerated statin to lower LDL-C among adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) in the US. Read more…
CP101 Engraftment Drives Efficacy: Results From a Randomized, Placebo-Controlled Trial Evaluating CP101, an Investigational Orally Administered Microbiome Therapeutic for Prevention of Recurrent C. difficile Infection
Introduction: Disruption of the microbiome is key to the pathogenesis of recurrent Clostridioides difficile infection (CDI). Read more…
Early Tocilizumab Dosing Is Associated With Improved Survival in Critically Ill Patients Infected With Severe Acute Respiratory Syndrome Coronavirus-2
Objectives: To identify the most efficacious timing for tocilizumab administration in critically ill patients infected with severe acute respiratory syndrome coronavirus-2. Read more…
Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2
Abstract: Tocilizumab is an IL-6 receptor antagonist with the ability to suppress the cytokine storm in critically ill patients infected with severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). Read more…
Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study
Objective: To characterize the real-world use, efficacy, and safety of oritavancin in adult patients with acute osteomyelitis. Read more…
